Interstitial Lung Disease / Pulmonary Fibrosis; Expanded Trial Landscape in October 2025
What Happened
According to a publication from the Pulmonary Fibrosis Foundation (PFF), October 2025 saw several trials enrolling volunteers across interstitial lung diseases (ILD), including pulmonary fibrosis (PF).
Why It Matters
ILD and PF remain major unmet-need areas. Increased trial activity suggests resurgence of research interest; likely including novel antifibrotic therapies, combination regimens, or biomarker-driven investigation. For Kitsa, this could open avenues beyond neuro/cancer; expanding into pulmonology, chronic disease, and newer therapy domains.
What to Watch
- →New trial protocols
Drug therapy, inhaled agents, biomarker studies, antifibrotics
- →Patient recruitment capacity
Inclusion of remote sites / diverse geographies (as lung disease trials often need large, varied cohorts)
- →Demands on trial infrastructure
Imaging, radiology, longitudinal follow-ups which align with Kitsa's strengths
Kitsa Platform Opportunity
The expansion of ILD and pulmonary fibrosis trials represents a strategic opportunity for Kitsa to extend beyond neuro and oncology into pulmonology and chronic disease. These trials require large, diverse patient cohorts, sophisticated imaging infrastructure, and long-term follow-up capabilities; all areas where Kitsa's platform and site network can provide significant value.